Semaglutide study for fatty liver and how sugar affects the liver
Treatments studied
Part of Digestive system clinical trials.
This Phase 2 study tests how semaglutide (a diabetes medication also used for weight) affects fatty liver and the liver’s response to sugar. It may help people with non-alcoholic fatty liver disease understand whether the drug improves liver fat and related changes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be age 18 or older and able to sign consent
- Have evidence of fatty liver within the last 12 months (biopsy or scan)
- Not drink alcohol heavily in the last 6 months (and no binge drinking)
- For the treatment group: fatty liver on biopsy plus at least 10% liver fat on a special MRI scan
- Be able to safely have repeat liver biopsies and MRI scans
- Avoid pregnancy or breastfeeding during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether adding a new medicine, CS0159, to a standard diabetes drug (semaglutide) can improve liver health and blood sugar in people with fatty liver disease, obesity, and type 2 diabetes. It may help reduce liver fat and support weight loss.
This trial tests semaglutide (a diabetes/weight-loss medicine) to help prevent weight gain after liver transplant. It is also looking at blood sugar and safety while you continue your transplant medicines.
This study tests whether an oral medication called semaglutide can help people with type 2 diabetes, fatty liver, and kidney problems. It aims to see if it can improve kidney function and liver health.
This study tests if an oral semaglutide pill can reduce liver fat and improve body composition in people who have had a liver transplant and have diabetes. It may help manage weight and blood sugar after transplant.
This study looks at whether semaglutide (a diabetes medication) affects belly fat and the liver in people who have both type 2 diabetes and chronic kidney disease. It aims to understand if the drug can improve these health markers even in patients with reduced kidney function.
This study looks at liver fat and how to manage it in people with obesity. It may help find better ways to treat fatty liver disease.
Hear when a new Non-Alcoholic Steatohepatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.